Table 3.

Comparison of the baseline characteristics of the thiazolidinedione arms of the studies showing versus not showing an increase in subcutaneous fat mass in HIV-infected HAART-treated patients. HAART = highly active antiretroviral therapy, SAT = subcutaneous adipose tissue, NR = not reported.

	Drug (dose/d)	Duration	Inclusion criteria	BMI (kg/m2)	% taking stavudine	Reference
No change in SAT	Rosi 8 mg	24 weeks	Lipoatrophy	24	67	Sutinen et al. [55]
	Rosi 8 mg	48 weeks	Lipoatrophy	23	49	Carr et al. [56]
	Pio 30–45 mg	12 months	Insulin resistance and dyslipidemia	26	NR	Gavrila et al. [65]
	Rosi 4 mg	24 weeks	Lipodystrophy	25	NR	Cavalcanti et al. [62]
Increase in SAT	Rosi 4 mg	3 months	Lipoatrophy and insulin resistance	26	44	Hadigan et al. [57]
	Rosi 4 mg	16 weeks	Lipodystrophy and insulin resistance	Body weight 80 kg	NR	Mulligan et al. [60]
	Pio 30 mg	48 weeks	Lipoatrophy	22	25	Slama et al. [66]
	Rosi 8 mg	26 weeks	Lipoatrophy	24	21	van Wijk et al. [58]